J Korean Ophthalmol Soc > Volume 57(3); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(3):429-437.
DOI: https://doi.org/10.3341/jkos.2016.57.3.429    Published online March 15, 2016.
Effects of Intravitreal Injection of Bevacizumab or Ranibizumab on Systemic Circulation.
Myung Hun Yoon, Young Jun Kim, So Young Lee, Kang Won Lee, Hee Seung Chin
Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea. hschin@inha.ac.kr
유리체내 베바시주맙과 라니비주맙 주입술이 전신 순환에 미치는 영향
윤명헌⋅김영준⋅이소영⋅이강원⋅진희승
인하대학교 의과대학 안과학교실
Abstract
PURPOSE
The purpose of this study was to evaluate the systemic effects of ranibizumab and bevacizumab by examining the plasma levels of anti-vascular endothelial growth factor (anti-VEGF) and VEGF before and after a single intravitreal injection. METHODS: Twenty-eight eyes of 28 patients with various retinal diseases were enrolled. Seventeen eyes received an injection of intravitreal bevacizumab, and 11 eyes received an injection of ranibizumab. Blood samples were collected just before and 1 day, 1 week, and 1 month after injection. Concentrations of anti-VEGF and VEGF in plasma were measured using enzyme-linked immunosorbent assay (ELISA). RESULTS: In the bevacizumab group, anti-VEGF concentration before the injection was 91.0 ng/mL, while those at 1 day, 1 week, and 1 month post-injection increased to 153.6, 196.3, and 140.3 ng/mL, respectively (p < 0.05 for all). VEGF concentration before the injection was 93.9 pg/mL, while those 1 day, 1 week, and 1 month post-injection were reduced to 40.1, 24.7, and 33.5 pg/mL, respectively (p < 0.05 for all). However, in the ranibizumab group, no significant reductions in anti-VEGF concentration were observed. The anti-VEGF concentration before the injection was 177.6 ng/mL, while those at 1 day, 1 week, and 1 month post-injection were 177.5, 160.7, 175.3 ng/mL, respectively (p > 0.05 for all). VEGF level also showed no significant change. VEGF concentration before the injection was 80.9 pg/mL, while those at 1 day, 1 week and 1 month post-injection were 96.7, 106.3, 106.1 pg/mL, respectively (p > 0.05 for all). CONCLUSIONS: Contrary to ranibizumab, intravitreal bevacizumab significantly lowers plasma VEGF level in patients with various retinal diseases. The study suggests the consideration of the systemic effects of intravitreal bevacizumab injection.
Key Words: Anti-vascular endothelial growth factor (anti-VEGF);Bevacizumab, Ranibizumab;Vascular endothelial growth factor (VEGF)


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next